| Literature DB >> 28060903 |
Jérôme Allyn1,2, Nicolas Allou1,2, Pascal Augustin2, Ivan Philip2,3, Olivier Martinet1, Myriem Belghiti1, Sophie Provenchere2, Philippe Montravers2,4, Cyril Ferdynus5,6.
Abstract
BACKGROUND: The benefits of cardiac surgery are sometimes difficult to predict and the decision to operate on a given individual is complex. Machine Learning and Decision Curve Analysis (DCA) are recent methods developed to create and evaluate prediction models. METHODS AND FINDING: We conducted a retrospective cohort study using a prospective collected database from December 2005 to December 2012, from a cardiac surgical center at University Hospital. The different models of prediction of mortality in-hospital after elective cardiac surgery, including EuroSCORE II, a logistic regression model and a machine learning model, were compared by ROC and DCA. Of the 6,520 patients having elective cardiac surgery with cardiopulmonary bypass, 6.3% died. Mean age was 63.4 years old (standard deviation 14.4), and mean EuroSCORE II was 3.7 (4.8) %. The area under ROC curve (IC95%) for the machine learning model (0.795 (0.755-0.834)) was significantly higher than EuroSCORE II or the logistic regression model (respectively, 0.737 (0.691-0.783) and 0.742 (0.698-0.785), p < 0.0001). Decision Curve Analysis showed that the machine learning model, in this monocentric study, has a greater benefit whatever the probability threshold.Entities:
Mesh:
Year: 2017 PMID: 28060903 PMCID: PMC5218502 DOI: 10.1371/journal.pone.0169772
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of patients at admission and evolution in ICU (whole dataset).
| Missing data | Total (n = 6,520) | Alive (n = 6,109) | Dead (n = 411) | ||
|---|---|---|---|---|---|
| Age, mean (sd), years | 0 | 63.4 (14.4) | 63.1 (14.5) | 68.2 (13.4) | < 0.0001 |
| Sex (male), n (%) | 0 | 4449 (68.2%) | 4178 (68.4%) | 271 (65.9%) | 0.30 |
| Weight, mean (sd), kg | 14 | 75.4 (14.9) | 75.6 (14.9) | 72.4 (15.0) | < 0.0001 |
| Height, mean (sd), cm | 19 | 168.5 (9.5) | 168.6 (9.5) | 166.7 (9.8) | < 0.0001 |
| BMI, mean (sd), kg.m-2 | 19 | 26.5 (4.6) | 26.5 (4.6) | 26.0 (4.9) | 0.02 |
| Comorbidities, n (%) | |||||
| Gastroduodenal ulcer | 0 | 288 (4.4%) | 265 (4.3%) | 23 (5.6%) | 0.23 |
| CancerNoYes, > 5 years agoYes, < 5 years agoUncontrolled without metastasesUncontrolled with metastases | 0 | 6002 (92.1%)238 (3.6%)195 (3.0%)66 (1.0%)19 (0.3%) | 5654 (92.5%)210 (3.4%)169 (2.8%)60 (1.0%)16 (0.3%) | 348 (84.7%)28 (6.8%)26 (6.3%)6 (1.5%)3 (0.7%) | < 0.0001 |
| Liver cirrhosisNoYes, uncomplicatedYes, complicated | 0 | 6455 (99.0%)40 (0.6%)25 (0.4%) | 6056 (99.1%)32 (0.5%)21 (0.3%) | 399 (97.1%)8 (1.9%)4 (1.0%) | 0.0002 |
| Immunodeficiency | 0 | 88 (1.3%) | 73 (1.2%) | 15 (3.7%) | < 0.0001 |
| Chronic pulmonary disease | 0 | 375 (5.8%) | 330 (5.4%) | 45 (10.9%) | < 0.0001 |
| Chronic obstructive pulmonary disease | 0 | 642 (9.9%) | 561 (9.2%) | 81 (19.7%) | < 0.0001 |
| Diabetes mellitus | 2 | 1674 (25.7%) | 1547 (25.3%) | 127 (31.0%) | 0.01 |
| Diabetes mellitus with insulin | 2 | 513 (7.9%) | 459 (7.5%) | 54 (13.2%) | < 0.0001 |
| Hypertension | 0 | 3678 (56.4%) | 3427 (56.1%) | 251 (61.1%) | 0.05 |
| Smoking (current or former) | 25 | 3336 (51.4%) | 3131 (51.4%) | 205 (50.5%) | 0.72 |
| Peripheral vascular disease | 0 | 905 (13.9%) | 829 (13.6%) | 76 (18.5%) | 0.005 |
| Chronic kidney disease requiring dialysis | 0 | 57 (0.9%) | 47 (0.8%) | 10 (2.4%) | 0.003 |
| Dyslipidemia | 0 | 3288 (50.4%) | 3100 (50.7%) | 188 (45.7%) | 0.05 |
| History of coronary artery disease | 0 | 2496 (38.3%) | 2351 (38.5%) | 145 (35.3%) | 0.19 |
| Myocardial infarction < 90 days | 0 | 440 (6.7%) | 411 (6.7%) | 29 (7.1%) | 0.80 |
| Previous cardiac surgery | 0 | 627 (9.6%) | 532 (8.7%) | 95 (23.1%) | < 0.0001 |
| History of endocarditis | 0 | 192 (2.9%) | 171 (2.8%) | 21 (5.1%) | 0.007 |
| History of cardiac congestive failure | 0 | 1047 (16.1%) | 919 (15.0%) | 128 (31.1%) | < 0.0001 |
| Angor Canadian Cardiovascular Society class01234 | 0 | 4919 (75.4%)165 (2.5%)949 (14.6%)436 (6.7%)51 (0.8%) | 4588 (75.1%)159 (2.6%)912 (14.9%)408 (6.7%)42 (0.7%) | 331 (80.5%)6 (1.5%)37 (9.0%)28 (6.8%)9 (2.2%) | < 0.0001 |
| History of thromboembolic event | 0 | 353 (5.4%) | 317 (5.2%) | 36 (8.8%) | 0.002 |
| Hemorrhagic stroke | 0 | 57 (0.9%) | 52 (0.8%) | 5 (1.2%) | 0.44 |
| Ischemic stroke | 0 | 464 (7.1%) | 415 (6.8%) | 49 (11.9%) | < 0.0001 |
| Poor mobility | 0 | 179 (2.7%) | 161 (2.6%) | 18 (4.4%) | 0.04 |
| Mediastinal radiotherapy | 0 | 122 (1.9%) | 111 (1.8%) | 11 (2.7%) | 0.21 |
| Supraventricular arrhythmiaNoYes, paroxysmalYes, permanent | 0 | 5148 (79.0%)646 (9.9%)726 (11.1%) | 4886 (80.0%)570 (9.3%)653 (10.7%) | 262 (63.7%)76 (18.5%)73 (17.8%) | < 0.0001 |
| Ventricular arrhythmia | 0 | 103 (1.6%) | 95 (1.6%) | 8 (1.9%) | 0.54 |
| Pacemaker | 0 | 222 (3.4%) | 189 (3.1%) | 33 (8.0%) | < 0.0001 |
| Atrial fibrillation | 0 | 776 (11.9%) | 696 (11.4%) | 80 (19.5%) | < 0.0001 |
| New York Heart Association class1234 | 0 | 1374 (21.1%)603 (9.2%)214 (40.1%)1929 (29.6%) | 1307 (21.4%)587 (9.6%)2496 (40.9%)1719 (28.1%) | 67 (16.3%)16 (3.9%)118 (28.7%)210 (51.1%) | < 0.0001 |
| Congestive heart failure | 0 | 255 (3.9%) | 200 (3.3%) | 55 (13.4%) | < 0.0001 |
| Active endocarditis | 0 | 202 (3.1%) | 172 (2.8%) | 30 (7.3%) | < 0.0001 |
| Critical preoperative state | 0 | 107 (1.6%) | 71 (1.2%) | 36 (8.8%) | < 0.0001 |
| Preoperative treatment, n (%) | |||||
| Antiplatelet therapyNoneAspirin onlyOthers | 0 | 2716 (41.7%)2666 (40.9%)1138 (17.4%) | 2526 (41.3%)2519 (41.2%)1064(17.4%) | 190 (46.2%)147 (35.8%)74 (18.0%) | 0.08 |
| Beta blocker | 0 | 3887 (59.6%) | 3661 (59.9%) | 226 (55.0%) | 0.05 |
| Anti-arrhythmic | 0 | 880 (13.5%) | 796 (13.0%) | 84 (20.4%) | < 0.0001 |
| Statin | 0 | 3837 (58.8%) | 3636 (59.5%) | 201 (48.9%) | < 0.0001 |
| Diuretic | 0 | 2359 (36.2%) | 2125 (34.8%) | 234 (56.9%) | < 0.0001 |
| Calcium Channel Blockers | 0 | 1298 (19.9%) | 1217 (19.9%) | 81 (19.7%) | 0.92 |
| Angiotensin-converting enzyme inhibitor | 0 | 3313 (50.8%) | 3117 (51.0%) | 196 (47.7%) | 0.19 |
| Nitrate treatment | 0 | 85 (1.3%) | 79 (1.3%) | 6 (7.1%) | 0.77 |
| Preoperative data’s | |||||
| Hemoglobin concentration, mean (sd), g.dL-1 | 20 | 13.3 (1.8) | 13.4 (1.7) | 12.4 (2.1) | < 0.0001 |
| Platelet numeration, mean (sd), x109.L-1 | 59 | 232.9 (78.3) | 233.3 (77.3) | 227.3 (91.1) | 0.01 |
| Prothrombin activity, mean (sd), % | 91 | 83.3 (12.6) | 89.8 (12.1) | 84.5 (17.1) | < 0.0001 |
| Serum creatinine, mean (sd), μg.L-1 | 27 | 99.5 (62.6) | 97.8 (59.8) | 124.8 (91.8) | < 0.0001 |
| Creatinine clearance (Cockcroft), mean (sd), mL.min-1 | 37 | 77.7 (32.7) | 78.9 (32.5) | 60.3 (29.5) | < 0.0001 |
| Creatinine clearance (MDRD), mean (sd), mL.min-1 | 38 | 75.7 (25.3) | 76.5 (25.0) | 63.9 (27.7) | < 0.0001 |
| Left ventricular ejection fraction, mean (sd), % | 2 | 57.9 (12.2) | 58.1 (12.0) | 54.7 (13.7) | < 0.0001 |
| Systolic pulmonary arterial pressure, mean (sd), mm Hg | 0 | 31.9 (12.6) | 31.6 (12.3) | 36.7 (15.0) | < 0.0001 |
| Preoperative coronary angiography, n (%) | |||||
| Coronary disease | 0 | 3253 (49.9%) | 3069 (50.2%) | 184 (44.8%) | 0.03 |
| Number of vessel-disease01234 | 0 | 3211 (49.2%)487 (7.5%)624 (9.6%)2079 (31.9%)119 (1.8%) | 3002 (49.1%)445 (7.3%)588 (9.6%)1959 (32.1%)115 (1.9%) | 209 (50.8%)42 (10.2%)36 (8.8%)120 (29.2%)4 (1.0%) | 0.10 |
| Valve disease | 0 | 3810 (58.4%) | 3526 (57.7%) | 284 (69.1%) | < 0.0001 |
| Functional tricuspid insufficiency | 0 | 693 (10.6%) | 630 (10.3%) | 63 (15.3%) | 0.001 |
| Ascending aortaNoAneurysmDissection | 0 | 6026 (92.4%)435 (6.7%)59 (0.9%) | 5652 (92.5%)410 (6.7%)47 (0.8%) | 374 (91.0%)25 (6.1%)12 (2.9%) | < 0.0001 |
| Congenital heart disease | 0 | 88 (1.3%) | 87 (1.4%) | 1 (0.2%) | 0.05 |
| Surgery characteristics, n (%) | |||||
| Number of surgical procedureisolated CABGSingle no-CABG2 procedures3 procedures | 0 | 2504 (38.4%)2176 (33.4%)1511 (23.2%)329 (5.0%) | 2399 (39.3%)2038 (33.4%)1388 (22.7%)284 (4.6%) | 105 (25.5%)138 (33.6%)123 (29.9%)45 (10.9%) | < 0.0001 |
| Coronary surgery | 0 | 3127 (52.0%) | 2953 (48.3%) | 174 (42.3%) | 0.02 |
| Valve surgery | 0 | 3649 (56.0%) | 3376 (55.3%) | 273 (66.4%) | < 0.0001 |
| Aortic valve surgery | 0 | 2382 (36.5%) | 2214 (36.4%) | 168 (40.9%) | 0.06 |
| Mitral valve surgery | 0 | 1517 (23.3%) | 1387 (22.7%) | 130 (31.6%) | < 0.0001 |
| Tricuspid valve surgery | 0 | 765 (11.7%) | 691 (11.3%) | 74 (18.0%) | < 0.0001 |
| Thoracic aorta surgery | 0 | 569 (0.7%) | 523 (8.6%) | 46 (8.1%) | 0.07 |
BMI: Body Mass Index; CABG: Coronary artery bypass grafting; MDRD: Modification of the Diet in Renal Disease.
Comparison of model performances on the validation dataset.
| AUC | 95%CI | |
|---|---|---|
| EuroSCORE I | 0.719 | 0.674–0.763 |
| EuroSCORE II | 0.737 | 0.691–0.783 |
| Logistic Regression Model (EuroSCORE II covariates) | 0.742 | 0.698–0.785 |
| Gradient Boosting Machine | 0.786 | 0.748–0.826 |
| Random Forests | 0.786 | 0.747–0.825 |
| Naïve Bayes | 0.734 | 0.689–0.779 |
| Support Vector Machine | 0.753 | 0.710–0.797 |
| Gradient Boosting Machine | 0.784 | 0.743–0.824 |
| Random Forests | 0.788 | 0.748–0.827 |
| Naïve Bayes | 0.750 | 0.708–0.793 |
| Support Vector Machine | 0.736 | 0.689–0.784 |
| Ensemble of ML Algorithms: ML model | 0.795 | 0.755–0.834 |
ML: Machine Learning.
†P value < 0.0001 compared with EuroSCORE II and with Logistic Regression Model.
Fig 1Receiver operating characteristic curves showing the performance of EuroSCORE I, EuroSCORE II, and the ML model in predicting post-operative mortality.
Areas under curves (95% CI) are 0.719 (0.674–0.763), 0.737 (0.691–0.783), and 0.795 (0.755–0.834), respectively.
Fig 2Decision curves showing the clinical usefulness of EuroSCORE I, EuroSCORE II, and the ML model in predicting post-operative mortality.
The blue line represents the net benefit of providing surgery for all patients, assuming that all patients would survive. The red line represents the net benefit of surgery to none patients, assuming that all would die after surgery. The green, purple and turquoise lines represent the net benefit of applying surgery to patients according to EuroSCORE I, EuroSCORE II, and ML model, respectively. The selected probability threshold (i.e., the degree of certitude of postoperative mortality over which the patient's decision is not to operate) is plotted on the abscissa.